$19.16
1.64% today
Nasdaq, Feb 28, 04:13 pm CET
ISIN
US7207951036
Symbol
PVLA
Sector
Industry

Pieris Pharmaceuticals, Inc. Stock price

$18.85
+5.95 46.12% 1M
+1.08 6.08% 6M
+6.85 57.08% YTD
+6.00 46.72% 1Y
-228.35 92.37% 3Y
-233.15 92.52% 5Y
-241.15 92.75% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.05 0.27%
ISIN
US7207951036
Symbol
PVLA
Sector
Industry

Key metrics

Market capitalization $211.52m
Enterprise Value $192.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 142.34
P/S ratio (TTM) P/S ratio 156.68
P/B ratio (TTM) P/B ratio 1.53
Revenue growth (TTM) Revenue growth -97.15%
Revenue (TTM) Revenue $1.35m
EBIT (operating result TTM) EBIT $-18.10m
Free Cash Flow (TTM) Free Cash Flow $-27.99m
Cash position $19.36m
EPS (TTM) EPS $-12.61
P/S forward 8,214.37
EV/Sales forward 7,462.52
Short interest 2.12%
Show more

Is Pieris Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Pieris Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Pieris Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.35 1.35
97% 97%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
11% 11%
998%
- Research and Development Expense 6.01 6.01
88% 88%
445%
-18 -18
5% 5%
-1,359%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -18 -18
17% 17%
-1,341%
Net Profit -16 -16
43% 43%
-1,181%

In millions USD.

Don't miss a Thing! We will send you all news about Pieris Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pieris Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
3 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) (the “Company”) and Palvella Therapeutics, Inc. Upon completion of the proposed transaction, Pieris shareholders are expected to own approximately 18% of the combine...
Neutral
GlobeNewsWire
5 months ago
Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of...
Neutral
GlobeNewsWire
5 months ago
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
More Pieris Pharmaceuticals, Inc. News

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Head office United States
CEO Wesley Kaupinen
Employees 50
Founded 2001
Website www.palvellatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today